Wang et al. BMC Cancer 2010, 10:415 http://www.biomedcentral.com/1471-2407/10/415 15. Ginzkey C, Eicker SO, Marget M, Krause J, Brecht S, Westphal M, Hugo HH, Mehdorn HM, Steinmann J, Hamel W: Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model. Cancer Immunol Immunother 2009, 59(4):541-51. 16. Wu A, Oh S, Gharagozlou S, Vedi RN, Ericson K, Low WC, Chen W, Ohlfest JR: In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. J Immunother 2007, 30(8):789-797. 17. Meng Y, Kujas M, Marie Y, Paris S, Thillet J, Delattre JY, Carpentier AF: Expression of TLR9 within human glioblastoma. J Neurooncol 2008, 88(1):19-25. 18. Kononen J, Bubendorf L, Kallionimeni A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallionimeni O-P: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4(7):844-847. 19. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H: Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002, 32(7):1958-1968. 20. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G: Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002, 168(9):4531-4537. 21. Yasuda H, Leelahavanichkul A, Tsunoda S, Dear JW, Takahashi Y, Ito S, Hu X, Zhou H, Doi K, Childs R, et al: Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury. Am J Physiol Renal Physiol 2008, 294(5):F1050-1058. 22. Ohgaki H, Kleihues P: Population-Based Studies on Incidence, Survival Rates, and Genetic Alterations in Astrocytic and Oligodendroglial Gliomas. Journal of Neuropathology & Experimental Neurology 2005, 64(6):479-489. 23. Scheurer ME, Bondy ML, Aldape KD, Albrecht T, El-Zein R: Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol 2008, 116(1):79-86. 24. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, Nabors LB, Cobbs CG, Britt WJ: Human Cytomegalovirus Infection and Expression in Human Malignant Glioma. Cancer Res 2002, 62(12):3347-3350. 25. Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, Sampson JH: Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro- oncol 2008, 10(1):10-18. 26. Iversen A-C, Steinkjer B, Nilsen N, Bohnhorst J, Moen SH, Vik R, Stephens P, Thomas DW, Benedict CA, Espevik T: A Proviral Role for CpG in Cytomegalovirus Infection. J Immunol 2009, 182(9):5672-5681. 27. Wagner H: The immunobiology of the TLR9 subfamily. Trends Immunol 2004, 25(7):381-386. 28. Takeshita F, Gursel I, Ishii KJ, Suzuki K, Gursel M, Klinman DM: Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin Immunol 2004, 16(1):17-22. 29. Rayburn ER, Wang W, Zhang R, Wang H: Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Int J Oncol 2007, 30(6):1511-1519. 30. Lin Y, Jiang T, Zhou K, Xu L, Chen B, Li G, Qiu X, Zhang W, Song SW: Plasma IGFBP-2 levels predict clinical outcomes of patients with high- grade gliomas. Neuro Oncol 2009, 11(5):468-476. 31. Sanai N, Berger MS: Operative techniques for gliomas and the value of extent of resection. Neurotherapeutics 2009, 6(3):478-486. 32. Hess KR: Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol 1999, 42(3):227-231. 33. Pang BC, Wan WH, Lee CK, Khu KJ, Ng WH: The role of surgery in high- grade glioma–is surgical resection justified? A review of the current knowledge. Ann Acad Med Singapore 2007, 36(5):358-363. 34. Chinnaiyan P, Wang M, Rojiani AM, Tofilon PJ, Chakravarti A, Ang KK, Zhang HZ, Hammond E, Curran W, Mehta MP: The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group. Radiat Oncol 2008, 3:32. Page 11 of 11 35. Reithmeier T, Graf E, Piroth T, Trippel M, Pinsker MO, Nikkhah G: BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors. BMC Cancer 10:30. 36. Batchelor TT, Betensky RA, Esposito JM, Pham LD, Dorfman MV, Piscatelli N, Jhung S, Rhee D, Louis DN: Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 2004, 10(1 Pt 1):228-233. 37. Jukkola-Vuorinen A, Rahko E, Vuopala KS, Desmond R, Lehenkari PP, Harris KW, Selander KS: Toll-Like Receptor-9 Expression Is Inversely Correlated with Estrogen Receptor Status in Breast Cancer. Journal of Innate Immunity 2009, 1(1):59-68. 38. Lee J-W, Choi J-J, Seo ES, Kim MJ, Kim WY, Choi CH, Kim T-J, Kim B-G, Song SY, Bae D-S: Increased toll-like receptor 9 expression in cervical neoplasia. Molecular Carcinogenesis 2007, 46(11):941-947. 39. Briceno E, Calderon A, Sotelo J: Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surg Neurol 2007, 67(4):388-391. 40. Briceno E, Reyes S, Sotelo J: Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. Neurosurg Focus 2003, 14(2): e3.. 41. Carpentier A, Laigle-Donadey F, Zohar S, Capelle L, Behin A, Tibi A, Martin- Duverneuil N, Sanson M, Lacomblez L, Taillibert S, et al: Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro-oncol 2006, 8(1):60-66. 42. Carpentier AF, Xie J, Mokhtari K, Delattre JY: Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 2000, 6(6):2469-2473. 43. Ginzkey C, Eicker SO, Marget M, Krause J, Brecht S, Westphal M, Hugo HH, Mehdorn HM, Steinmann J, Hamel W: Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model. Cancer Immunol Immunother 59(4):541-551. 44. Deng G-M, Liu Z-Q, Tarkowski A: Intracisternally Localized Bacterial DNA Containing CpG Motifs Induces Meningitis. J Immunol 2001, 167(8):4616-4626. 45. Carpentier A, Metellus P, Ursu R, Zohar S, Lafitte F, Barrie M, Meng Y, Richard M, Parizot C, Laigle-Donadey F, et al: Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol 12(4):401-408. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/10/415/prepub doi:10.1186/1471-2407-10-415 Cite this article as: Wang et al.: TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients. BMC Cancer 2010 10:415. Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color ﬁgure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit